Amyris and Koninklijke DSM NV announced that they have agreed for DSM to make an equity investment in Amyris. At the same time, the companies will enter into a development cooperation focused on products for the global health and nutrition markets (including vitamins and other nutritional ingredients).
DSM has agreed to make an initial equity investment in Amyris of US$25 million, translating into a shareholding of ~12%. Subject to the satisfaction of certain conditions, DSM may invest an additional US$25 million in Amyris. As part of the agreement, DSM and Amyris have agreed to focus on a number of short- to mediumterm product development & production opportunities in vitamins and other nutritional ingredients
“We are very excited about DSM’s strategic focus in health and nutrition markets and its commitment to sustainable sourcing and production of better-performing products,” said John Melo, Amyris President & CEO.”
“Amyris has a unique yeastbased strain engineering platform that is very complementary to DSM’s capabilities in this area and will create great synergy with DSM’s know-how in fermentation, downstream process development and large-scale manufacturing,” said Chris Goppelsroeder, president & CEO of DSM Nutritional Products.
